UNSPSC 51102863: Neomycin/polymyxin b

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.

UNSPSC 51102863 Neomycin/polymyxin b is a Commodity code that covers antibiotic pharmaceutical products, but recent state and local solicitations tagged under this code do not reflect procurement of this specific drug. Instead, the opportunities posted show state and local governments acquiring broader categories of medical supplies, pharmaceuticals, and pharmacy services — including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, medical and first aid supplies for emergency response, and direct-to-manufacturer prescription program capabilities. The issuing bodies span diverse jurisdictions: county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments and purchasing offices (City of Tampa), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon). The code shows limited alignment between its nominal scope — a specific antibiotic formulation — and the actual procurement activity being tagged to it, suggesting potential miscoding of these opportunities or a broader interpretation of pharmaceutical procurement under this classification.

Recent opportunities include Seminole County's invitation to bid (IFB 60459723LAS) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due by July 26, 2023; the City of Tampa's bid for medical and first aid supplies (26P00145) to support the Fire Department Rescue Division with an estimated contract value of $700,000 and a sheltered small local business enterprise set-aside; the Minnesota Multistate Cooperative Purchasing Alliance's RFP (S1070000015802) to establish multiple contracts for generic pharmaceuticals and OTC products with proposals due March 26, 2026; and the Texas HHS Commission's RFI (HHS0017013) soliciting vendor capabilities for a direct-to-manufacturer prescription program with a response deadline of April 3, 2026. Geographic activity concentrates in Florida, Texas, and the Upper Midwest (Minnesota and Oregon), with municipal and county-level procurement predominating in the South and cooperative purchasing vehicles more active in the North.